A Houston Methodist Research Institute study found older adults with MASLD on GLP-1-based treatment had lower risk of hospitalization and death.
Recap by typeshit. Full story at Medical Xpress.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
On the drug since November 2023, she says she still enjoys eating but food no longer takes over her life.
Dr Alo argues semaglutide's bigger story is heart protection, citing SELECT trial results showing fewer cardiovascular events in people without diabetes.
Loading…